Sign in
WithdrawnNo phase

Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer

Key facts

Who runs it
Guangzhou Bio-gene Technology Co., Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
11 Dec 2024
Ended
2 Mar 2026
Type of study
Interventional
Treatments tested
  • CAR-T
Record updated
28 May 2026
Why it stopped
Due to corporate strategic adjustment.

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Voluntarily participate in this trial, sign the informed consent form
  • Advanced colorectal cancer patients who have either failed standard treatment, experienced intolerable toxicity, or are unsuitable or unwilling to undergo standard treatment, and voluntarily agree to receive the current treatment
  • Be able to provide immunohistochemical (IHC) test results from the past 2 years, indicating positive expression of CDH17/GUCY2C targets in tumor tissues
  • Have at least one extracranial, measurable/assessable lesion according to RECIST 1.1 criteria
  • Have an ECOG (Eastern Cooperative Oncology Group) performance status score of 0-1 and an expected survival duration of at least 3 months
  • Have recovered from the toxicity associated with previous treatments, with a CTCAE toxicity grade of less than 2
  • Have no significant hematopoietic dysfunction and possess adequate organ function
  • Be able to meet the research center's requirements for apheresis/peripheral blood collection upon successful screening, or have acceptable stored blood cell separation products available

Who cannot take part

  • Patients who have undergone or are awaiting organ transplantation
  • Individuals who have received live (attenuated) virus vaccines within four weeks prior to screening
  • Individuals who have participated in other clinical trials involving drugs within the past 30 days
  • Patients who have had or currently have other malignant tumors within the past five years
  • History of clinically significant central nervous system disorders, either in the past or at screening
  • History of severe allergies
  • Patients with severe cardiac disease
  • Patients with severe hepatic and renal dysfunction or disorders of consciousness
  • Patients with active autoimmune or inflammatory diseases
  • Patients with objective evidence of past or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonia, severe lung function impairment, etc
  • Infections requiring intravenous antibiotic therapy for control or are uncontrollable
  • Alcoholics or individuals with a history of substance abuse
  • Patients who, based on the investigator's judgment and/or clinical standards, have contraindications to any study procedures or present other medical conditions that may pose unacceptable risks
  • Individuals who have received cytotoxic drugs or other interventions, assessed by the investigator as potentially impacting lymphocyte expansion, within 14 days or at least five half-lives (whichever is shorter) prior to blood collection for CAR-T preparation
  • Presence of brain metastasis
  • Imaging indicating tumor invasion of major blood vessels or indistinct borders with blood vessels
  • Presence of other viremias
  • Pregnant or lactating women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a single-arm, single-center investigator-initiated trial (IIT) designed to evaluate the safety and preliminary efficacy of CDH17/GUCY2C CAR-T cell therapy in patients with advanced colorectal cancer, as well as to assess its pharmacodynamic (PD) and pharmacokinetic (PK) profiles.

The group in the trial

  • CAR-TTreatment being tested

    The dosage range of 1.0 × 10\^6/kg (± 20%) to 5.0 × 10\^6/kg (± 20%) of CAR-T cells, administered either intravenously or intratumorally.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Study Evaluating the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer
Record updated
28 May 2026